Intravenous Pamidronate for Refractory Lymphedema

BACKGROUND: Based on beneficial reports of pamidronate use for reflex sympathetic dystrophy in reduction of pain and swelling, this drug can be studied as a novel treatment for refractory lymphedema. This study aims to determine the effectiveness of pamidronate on lymphedema and its possible side effects. METHODS: Twelve cases of lower limb refractory lymphedema were enrolled. They received intravenous pamidronate monthly for 3 consecutive months and were followed by measuring any discomfort with visual analog scale (VAS) and physician global assessment, based on objective signs of limb volume and circumference. RESULTS: The limb volume, circumference, and satisfaction of the patients improved significantly. CONCLUSION: Pamidronate when is added to conservative treatments may reduce lymphedema and improve the patient’s comfort.